Energy Homeostasis Under Treatment With Atypical Antipsychotics
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring weight gain, schizophrenia, atypical antipsychotics
Eligibility Criteria
Inclusion Criteria: Diagnosis of schizophrenia or related disorders(DSM-IV) Indication for long-term treatment with antipsychotics BMI between 20 to 30 Weight changes less than 3kg in the last 3 months before inclusion Informed consent Exclusion Criteria: Psychiatric comorbidity Depot antipsychotic in the last 2 months Antipsychotics in the last 2 weeks Treatment with olanzapine, clozapine or ziprasidone in teh last 3 months Treatment with drugs, that may lead to weight changes Significant endocrine, neurological, cardiovascular, hepatic, renal, metabolic, or other medical diseases or any clinically relevant abnormalities in laboratory tests Female subjects during pregnancy and breastfeeding Female subjects within childbearing years who were not using adequate birth control Patients who are judged by the investigator to be at serious suicide risk
Sites / Locations
- Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Olanzapine
Zpirasidone